NCT00568178
An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
See it on ClinicalTrials.gov ↗306 people
42.5%
57.5%
130 womenmiddle line = equal numbers176 men
- Phase
- PHASE3
- Paid for by
- Organon and Co
- Finished
- 2011-03-01
- Health conditions
- Proteinuria
- Who could join
- Anyone
- Ages
- 12 Months – 17 Years
- Average age
- mean 10.1 years
- Age 65+
- 0%
- Weight (BMI)
- mean 19.5 kilograms per meter squared (kg/m2)
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 52.9% · More than one race 22.9% · Asian 17% · Other 3.9% · Black / African American 3.3%
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 17 Years.”
- No pregnant women
Women who were pregnant could not join.
“Pregnant and/or nursing”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Requires cyclosporine to treat renal disease (kidney disease)”
Study titles and rules are shown in their original English.